Harsha Tankala, MD
Geriatric Medicine · Dover, DENPI 1164441242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 83 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$378
- Novo Nordisk$322
- Pfizer$148
- Johnson & Johnson$147
- Astellas Pharma US Inc$127
- GSK$79
- plus $462 from 10 others
What the payments were for
- Food & beverage$1,58895%
- Education$755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $378 |
| Novo Nordisk | 17 | $322 |
| Pfizer | 6 | $148 |
| Johnson & Johnson | 5 | $147 |
| Astellas Pharma US Inc | 4 | $127 |
| GSK | 4 | $79 |
| Merck | 4 | $79 |
| Lilly USA, LLC | 4 | $72 |
| Boehringer Ingelheim | 4 | $65 |
| Exact Sciences | 3 | $61 |
| Amgen | 3 | $53 |
| Dexcom, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| AbbVie | 1 | $13 |
How this compares
Too few geriatric medicine providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $108,106 |
| TrulicityDulaglutide | 61 | $90,388 |
| EliquisApixaban | 58 | $69,975 |
| MounjaroTirzepatide | 48 | $61,743 |
| JardianceEmpagliflozin | 38 | $57,783 |
| FarxigaDapagliflozin Propanediol | 41 | $43,219 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $42,386 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $38,899 |
| MyrbetriqMirabegron | 24 | $26,344 |
| XareltoRivaroxaban | 17 | $22,714 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $21,290 |
| JanuviaSitagliptin Phosphate | 19 | $18,665 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $12,380 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $12,300 |
| Atorvastatin Calcium | 683 | $11,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $72 | $152,131109 claims |
| Novo NordiskOzempic | $322 | $108,10664 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $378 | $82,11874 claims |
| PfizerEliquis, Abrysvo | $148 | $78,55785 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $79 | $68,95893 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $65 | $63,79851 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $26,34424 claims |
| Johnson & JohnsonXarelto | $147 | $22,71417 claims |
| MerckJanuvia | $79 | $18,66519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Dover
- Rooparani BhatHockessin$86
- Kulwant KlairNewark$79
- Manu SehgalMilford$44
- Ijaz AnwarMiddletown$0
- Linsey O'DonnellWilmington$0
- Lynsey BrandtWilmington$0
- Melissa Morgan-GouveiaWilmington$0
- Jeffrey GuarinoWilmington$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.